Bicycle Therapeutics (BCYC) Liabilities and Shareholders Equity (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $606.6 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 27.11% year-over-year to $606.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.7 billion (down 25.32% YoY) and the FY2025 annual result came in at $717.6 million, down 25.01% from the prior year.
• Liabilities and Shareholders Equity eased to $606.6 million in Q2 2026, from $652.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.1 billion in Q2 2024 to a low of $410.6 million in Q4 2022.
• A 5-year average of $659.1 million and a median of $622.6 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 132.81% — and 2026, when it decreased 27.11%.
• Tracing BCYC's Liabilities and Shareholders Equity over 5 years: stood at $410.6 million in 2022, then soared by 44.99% to $595.3 million in 2023, then jumped by 60.73% to $956.9 million in 2024, then declined by 25.01% to $717.6 million in 2025, then declined by 15.47% to $606.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $606.6 million (Q2 2026), $652.4 million (Q1 2026), and $717.6 million (Q4 2025), per Business Quant data.